Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Stelara® (ustekinumab) – Expanded indication
October 13, 2017 – Janssen announced the FDA approval of Stelara (ustekinumab) for adolescent patients (12 years or older) with moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy.
